Combined Operation Modality vs. Imatinib Mesylate Alone for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: the Randomized COMVIA Trial

DU Chunyan; ZHOU Ye; SONG Chun; WANG Yongpeng; JIE Zhigang; LIANG Xiaobo; HE Yulong; CAO Hui; YAN Zhongshu; SHI Yingqiang

Chinese︱Feedback︱Save this page

Combined Operation Modality vs. Imatinib Mesylate Alone for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: the Randomized COMVIA Trial

DU Chunyan 1 #,ZHOU Ye 2,SONG Chun 3,WANG Yongpeng 3,JIE Zhigang 4,LIANG Xiaobo 5,HE Yulong 6,CAO Hui 7,YAN Zhongshu 8,SHI Yingqiang 2 *

1.Department of Gastric Cancer and Soft Tissue Surgery, Cancer Center, Fudan University, ShangHai 200237

2.Department of Gastric Cancer and Soft Tissue Surgery, Cancer Center, Fudan University, Shanghai, 200237

3.Department of Colorectal Surgery, Liaoning Cancer Hospital & Institute, Shenyang, China

4.Department of General Surgery, the First Affiliated Hospital of Nanchang University, Nanchang, China,300006

5.Department of Colorectal Cancer, Shanxi Cancer Hospital, Taiyuan, Shanxi, 030013

6.Department of Gastrointestinal & Panceatic Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou,510080

7.Department of General Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,200127

8.Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, Hunan,410008

*Correspondence author

#Submitted by

Subject:

Funding: none

Opened online:29 January 2013

Accepted by: none

Citation: DU Chunyan,ZHOU Ye,SONG Chun.Combined Operation Modality vs. Imatinib Mesylate Alone for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: the Randomized COMVIA Trial[OL]. [29 January 2013] http://en.paper.edu.cn/en_releasepaper/content/4514217

Objectives:Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. For advanced GIST patients who are responding to imatinib mesylate, the role of surgery has not been formally demonstrated. Therefore, this multicenter, randomized, controlled trial was designed to assess whether surgeries to treat residual disease for patients with recurrent/metastatic GISTs responding to imatinib mesylate (IM) improves progression free survival (PFS) compared with IM treatment alone. Methods: Between 3 and 12 months after starting molecular-targeted therapy with IM for recurrent/metastatic GISTs, eligible patients were randomized to two arms: Arm A (surgery for residual disease) and Arm B (IM treatment alone). In Arm A (19 pts), surgery was performed to remove residual macroscopic lesions as completely as possible, and IM treatment continued after surgery. In Arm B (22 pts), IM was given alone at a dose of 400mg per day until disease progression. The primary endpoint was PFS, measured from the date IM starts. This study is registered in the ChiCTR registry with the ID number ChiCTR-TRC-00000244. Results: This randomized trial was closed early due to poor accrual. Only 41 patients were enrolled as opposed to 210 planned. After a median follow-up of 23 months (ranging from 15-34 months), the 2-year PFS was 88.4% in the surgery arm and 57.7% in the IM-alone arm (P=0.089). A trend towards survival benefit is observed in the surgery arm; however, it did not result in a statistically significant improvement in PFS. The most likely reason was the limited number of eligible patients, which was well below expectation. Conclusions: Surgeries to treat residual disease for patients with recurrent/metastatic GISTs responding to IM showed a trend to prolonging 2-year PFS compared with IM treatment alone, but no statistically significant conclusion is drawn from the study.

Keywords:Gastrointestinal stromal tumors; imatinib mesylate; surgery

For this paper

● PDF (0B)
● Revision 0 　　
● Print this paper
● Recommend this paper to a friend
● Add to my favorite list

Saved Papers

Please enter a name for this paper to be shown in your personalized Saved Papers list

Tags

Add yours

Related Papers

Statistics

PDF Downloaded	327
Bookmarked	0
Recommend	5
Comments	Array

Submit your papers

Alert Name:
Alerting to:
Authentication email will be sent to your email address in 24 hours
Frequency:
Email Message Format:	Plain text Graphical(HTML)

Complete the form below and we will recommend the selected titles to your friends on your behalf. * Indicates a required field.
Your name*:
Your email address*:
Recipient's name*:
Recipient's email address*:
(multiple recipient's names and email addresses should be separated with semicolons)
Your comments:	I thought you would find the page(s) useful.

Your name:
Your email address:
Recipient's name:
Recipient's email address:
(multiple recipient's names and email addresses should be separated with semicolons)
Your comments:	I thought you would find this page useful.

Disclaimer: This message was sent to your friend using the "Send it to a friend" facility on the Sciencepaper Online’ WWW site, http://www.paper.edu.cn/en. The Sciencepaper Online is not responsible for the content of this email, and anything said in this email does not necessarily reflect the Sciencepaper Online's views.

	Check out RSS, or use RSS reader to subscribe this item

Saved Papers